This article discusses comparisons involving Sinovac/AstraZeneca and Pfizer schedules, antibody measurements, and studies of AstraZeneca. A statement or recommendation in a video should not be treated as medically established without checking the underlying evidence and current public-health guidance.
What health studies can and cannot establish
- Comparisons may distinguish antibodies that bind to the spike protein from neutralizing antibodies. A laboratory result alone does not confirm every number shown in a chart or establish that one vaccine schedule is best for everyone.
- A randomized, open-label study in healthy adults in Thailand assessed immune responses and adverse events across several vaccine schedules. Its findings apply to the studied population, products, tests, and observation period; they are not a universal ranking of clinical effectiveness.
- Antibody results are laboratory measures. Their interpretation depends on the assay, virus variant, time since vaccination, and clinical outcomes. An antibody-only study does not establish present-day outbreak conditions in the United States or Israel.
How to read a vaccine chart
- Check the original study, participant number and characteristics, vaccine schedules and spacing, test method, and blood-collection dates.
- Distinguish anti-spike or binding-antibody results from neutralization results, and distinguish both from protection against infection or severe disease in real-world settings.
- For current vaccination decisions, follow the latest guidance from Thai public-health authorities and consult a clinician who knows your health history. Do not use a past outbreak or one chart to choose a schedule for yourself.
This information is for general education and to help prepare questions. It does not replace an examination, diagnosis, or an individual treatment plan. If symptoms persist or worsen, or you are considering changing medication or supplements, consult a healthcare professional.